Get the Stockscreener App
4.59
8.20%
-0.41
After Hours:
4.58
-0.010
-0.22%
Alumis Inc Stock (ALMS) Latest News
Drug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investor - The Business Journals
Metal-Organic Frameworks Market to Reach $949.2 Million by 2029, Growing at 15.6% CAGR - GlobeNewswire Inc.
Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy - BioSpace
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan - EIN News
Alumis (NASDAQ:ALMS) Receives Buy Rating from HC Wainwright - Defense World
How a skin drug trial could help Peninsula biotech pull off key merger - The Business Journals
H.C. Wainwright maintains Alumis stock Buy rating, $19 target By Investing.com - Investing.com South Africa
Alumis to Present at Leerink's 2025 Global Healthcare Conference - StockTitan
Promising Efficacy of Alumis Inc.’s ESK-001 in Psoriasis Treatment Boosts Market Position and Buy Rating - TipRanks
Alumis announces data from the OLE of its Phase 2 STRIDE trial - TipRanks
Alumis Says Phase 3 Onward Program Ongoing With Topline Data Expected In Q1 2026 - Marketscreener.com
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis - The Manila Times
New Psoriasis Drug Maintains Remarkable 61% Skin Clearance After One YearKey Trial Results - StockTitan
Acelyrin, Alumis reaffirm strategic, financial rationale of proposed merger - TipRanks
Acelyrin falls as Acelyrin reaffirms deal commitment - MSN
Acelyrin rebuffs Concentra bid, believing Alumis option better - The Pharma Letter
Acelyrin Rejects Concentra’s Buyout Offer in Favor of Alumis Merger - BioSpace
Promising Developments in Alumis Inc.’s Clinical Programs Support Buy Rating - TipRanks
Acelyrin To Proceed With Alumis Merger, Spurn Concentra Bid - Citeline News & Insights
Sector Update: Health Care Stocks Lower Tuesday Afternoon -March 04, 2025 at 02:01 pm EST - Marketscreener.com
Acelyrin Reaffirms Merger Deal With Alumis -March 04, 2025 at 10:13 am EST - Marketscreener.com
Acelyrin stock falls on Acelyrin deal commitment (SLRN:NASDAQ) - Seeking Alpha
Alumis Inc. Announces Merger with ACELYRIN, Inc. - TipRanks
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger - The Manila Times
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger - The Manila Times
Alumis Inc. and ACELYRIN, Inc. Confirm Commitment to All-Stock Merger to Create Leading Biopharma Company in Immune-Mediated Diseases - Nasdaq
Alumis And Acelyrin Reaffirm Strategic And Financial Rationale Of Proposed Merger -March 04, 2025 at 09:06 am EST - Marketscreener.com
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not ... - Eagle-Tribune
Can This Biopharma Merger's $737M War Chest Transform Immune Disease Treatment? - StockTitan
Acelyrin stock down after reaffirming Alumis deal (SLRN:NASDAQ) - Seeking Alpha
Alumis (NASDAQ:ALMS) Given “Buy” Rating at HC Wainwright - Defense World
Promising Prospects for Alumis Inc.’s TYK2 Inhibitor A-005: Analyst Reiterates Buy Rating with $19 Price Target - TipRanks
Alumis presents new psoriasis drug data, eyes Phase 3 results in 2026 - Investing.com Australia
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout - The Manila Times
Alumis presents new psoriasis drug data, eyes Phase 3 results in 2026 By Investing.com - Investing.com South Africa
Can Alumis's Fast-Tracked Psoriasis Drug Challenge Market Leaders? Phase 3 Timeline Speeds Up - StockTitan
Alumis to present new data on multiple sclerosis therapy By Investing.com - Investing.com South Africa
Alumis to present new data on multiple sclerosis therapy - Investing.com
Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases - The Manila Times
Can Alumis' Brain-Penetrating Drug Transform Multiple Sclerosis Treatment? Phase 1 Results Suggest Yes - StockTitan
Counteroffer from Tang-backed Concentra could scuttle Acelyrin-Alumis: Deals Report - BioCentury
When (ALMS) Moves Investors should Listen - Stock Traders Daily
Alumis Inc. introduces severance and change in control plan By Investing.com - Investing.com Canada
Alumis Inc. Approves New Severance and Control Plan - TipRanks
Activist investor threatens drug maker's merger plans with L.A. biotech - The Business Journals
Alumis Inc. introduces severance and change in control plan - Investing.com India
Activist investor threatens Peninsula drug maker's merger plansSan Francisco Business Times - The Business Journals
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences - The Manila Times
Alumis (ALMS) to Release Earnings on Wednesday - MarketBeat
Acelyrin, Inc. Confirms Unsolicited Acquisition Proposal from Concentra Biosciences Amidst Ongoing Merger Agreement with Alumis Inc. - Nasdaq
Can This New Cash Offer Derail ACELYRIN's Planned Alumis Merger? - StockTitan
Analysts Set Alumis Inc. (NASDAQ:ALMS) Target Price at $26.57 - MarketBeat
Alumis Inc. (NASDAQ:ALMS) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Oppenheimer sets Alumis stock with Outperform, $32 target - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TURN, AMPS, SLRN on Behalf of Shareholders - The Malaysian Reserve
How To Trade (ALMS) - Stock Traders Daily
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):